Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

1(33.3%)

N/A

1(33.3%)

Phase 4

1(33.3%)

3Total

Phase 2(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT04271540Phase 4Completed

MIcrovascular dysfuNction In Moderate-severe Psoriasis

Role: lead

NCT02546388Not ApplicableCompleted

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Role: lead

NCT01756352Phase 2Completed

FET-PET for Evaluation of Response of Recurrent GBM to Avastin

Role: lead

NCT01240161Completed

Personalized Translational Platform for Biomarker Discovery in Brain Tumors

Role: lead

All 4 trials loaded